OncoMatch/Clinical Trials/NCT06503211
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
Is NCT06503211 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies UTAA09 for recurrent or refractory b-cell non hodgkin's lymphoma.
Treatment: UTAA09 — The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positivity
Required: CD20 positivity
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chimeric antigen receptor therapy
Received other chimeric antigen receptor therapy or gene modified cell therapy before screening
Cannot have received: gene modified cell therapy
Received other chimeric antigen receptor therapy or gene modified cell therapy before screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify